Program: Tuesday (06.11.2007)

08:30 – 10:00

Room: Großer Saal

Scientific Session Radiotherapy

  • Rolf-Peter Müller
  • Joachim Yahalom
  • Dose and Field Size: the EORTC Experience

    • Theodore Girinsky
  • Dose and Field Size: the GHSG Experience

    • Rolf-Peter Müller
  • Radioimmunotherapy (RIT) Applied to HL – a Useful Tool?

    • Tim Illidge
  • Yttrium-90 Radiolabeled Humanized Anti- CD25 Monoclonal Antibody, Daclizumab Provides Effective Therapy for Refractory and Relapsed HL

    • Thomas Waldmann
  • Involved Node Radiotherapy: Impact on Dose to PTV and Organs at Risk

    • Bart Reymen
  • Chemotherapy Alone versus Chemotherapy Plus Radiotherapy for Early Stage HL

    • Fareed A. Rehan

10:30 – 12:00

Room: Großer Saal

Scientific Session Allogenetic Transplantation

  • Christian Gisselbrecht
  • Aaron Polliack
  • Overview on Transplantation Strategies

    • Norbert Schmitz
  • Do we Need Allogeneic Transplantation in HL?

    • John Gribben
  • New Frontiers in Allogeneic Transplantation for HL

    • Paolo Anderlini
  • Reduced Intensity Allogeneic Stem Cell Transplantation (RIC-Allo) for Refractory / Relapsed HL. Preliminary Results of an EBMT Prospective Trial

    • Anna Sureda
  • Workshop Report

    • Christian Gisselbrecht

12:15 – 13:45

Room: Großer Saal

Satellite Symposium (by Lilly) Role of Gemcitabine in the Treatment of Hodgkins Lymphoma

  • Anas Younes
  • Development of Gemcitabine in HL – US Perspective

    • George Canellos
  • Development of Gemcitabine in HL – European Perspective

    • Henning Bredenfeld
  • New Perspectives in the Treatment of HL

    • Peter Borchmann
  • Lilly Oncology Pipeline

    • Marjo Hahka-Kemppinen
    • Eli Lilly

14:00 – 15:30

Room: Großer Saal

Scientific Session PET

  • Magnus Björkholm
  • Anton Hagenbeek
  • PET-CT for Treatment Response Assessment in Lymphoma

    • Sigrid Stroobants
  • PET for Early Response Adapted Therapy

    • Martin Hutchings
  • Current Role and Future of PET in HL

    • Bruce Cheson
  • FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in HL – Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG

    • Carsten Kobe
  • Early Interim FDG-PET Overshadows the Prognostic Role of IPS in Advanced-stage HL Treated by Conventional ABVD Therapy

    • Andrea Gallamini
  • Interim Results of a UK NCRI Randomised Trial Comparing Involved Field Radiotherapy with No Further Treatment after 3 Cycles ABVD and a “Negative” PET Scan in Clinical Stages IA/IIA

    • John Radford

16:00 – 17:30

Room: Großer Saal

Scientific Session Advanced Stages HL

  • Richard Fisher
  • Mads Hansen
  • North America: Cooperative Groups

    • Sandra Horning
  • EORTC

    • Patrice Carde
  • GHSG

    • Volker Diehl
  • Phase-II Study of Rituximab Plus ABVD for the Treatment of Newly Diagnosed Patients with Advanced Stage Classical HL

    • Anas Younes
  • High-dose Therapy and ASCT versus Conventional Therapy for Patients with Advanced HL Responding to Front-line Therapy: Long Term Results

    • Angelo Michele Carella
  • ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the Initial Treatment of Patients with Advanced HL. Preliminary Results of HD2000 GISL Trial

    • Massimo Federico

17:30 – 18:45

Room: Großer Saal

Main Program Closing Remarks

  • Andreas Engert

19:00

Room: tba

Main Program Speakers Dinner

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.